ABSTRACT
Sudden cardiac death (SCD) is an unexpected and dramatic event. It draws special attention especially in young, seemingly healthy athletes. Our scientific paper is based on the death of a young, 23-year-old professional footballer, who died on the football field after a two-year history of cardiac symptoms. In this study we analyzed clinical, ECG and laboratory data, as well as results of genetic testing analysis in family members. To elucidate potential genetic etiology of SCD in this family, our analysis included 294 genes related to various cardiac conditions.
ABSTRACT
Injectable hydrogel biomaterials are promising therapies to promote repair and regeneration post-myocardial infarction (MI). However, the timing of delivery and the mechanisms through which biomaterial treatments confer their benefits are translational issues that remain to be addressed. We assessed the efficacy of an injectable collagen matrix at 3 different delivery time points post-MI. Infarcted mice received the matrix or control (saline) treatment at 3 h, 1 week or 2 weeks after MI. The earlier treatment delivery better prevented negative ventricular remodeling and long-term deterioration of cardiac function (up to 3 months), whereas waiting longer to administer the matrix (1 and 2 weeks post-MI) reduced the therapeutic effects. Collagen matrix delivery did not stimulate an inflammatory response acutely and favorably modulated inflammation in the myocardium long-term. We found that the matrix interacts with the host tissue to alter the myocardial cytokine profile, promote angiogenesis, and reduce fibrosis and cell death. This work highlights that the timing of delivery can significantly affect the ability of an injectable hydrogel to protect the post-MI environment, which will be an important consideration in the clinical translation of cardiac biomaterial therapy.
Subject(s)
Biocompatible Materials/chemistry , Biocompatible Materials/therapeutic use , Hydrogel, Polyethylene Glycol Dimethacrylate/chemistry , Myocardial Infarction/drug therapy , Animals , Collagen , Echocardiography , Extracellular Matrix/metabolism , Hydrogel, Polyethylene Glycol Dimethacrylate/therapeutic use , Immunohistochemistry , Male , Mice , Mice, Inbred C57BLABSTRACT
BACKGROUND: Cell transplantation for regenerative medicine has become an appealing therapeutic method; however, stem and progenitor cells are not always freshly available. Cryopreservation offers a way to freeze cells as they are generated, for storage and transport until required for therapy. This study was performed to assess the feasibility of cryopreserving peripheral blood mononuclear cells (PBMCs) for the subsequent in vitro generation of their derived therapeutic population, circulating angiogenic cells (CACs). METHODS: PBMCs were isolated from healthy human donors. Freshly isolated cells were either analyzed immediately or cryopreserved in media containing 6% plasma serum and 5% dimethyl sulfoxide. PBMCs were thawed after being frozen for 1 (early thaw) or 28 (late thaw) days and analyzed, or cultured for 4 days to generate CACs. Analysis of the cells consisted of flow cytometry for viability and phenotype, as well as functional assays for their adhesion and migration potential, cytokine secretion, and in vivo angiogenic potential. RESULTS: The viability of PBMCs and CACs as well as their adhesion and migration properties did not differ greatly after cryopreservation. Phenotypic changes did occur in PBMCs and to a lesser extent in CACs after freezing; however the potent CD34(+)VEGFR2(+)CD133(+) population remained unaffected. The derived CACs, while exhibiting changes in inflammatory cytokine secretion, showed no changes in the secretion of important regenerative and chemotactic cytokines, nor in their ability to restore perfusion in ischemic muscle. CONCLUSION: Overall, it appears that changes do occur in cryopreserved PBMCs and their generated CACs; however, the CD34(+)VEGFR2(+)CD133(+) progenitor population, the secretion of pro-vasculogenic factors, and the in vivo angiogenic potential of CACs remain unaffected by cryopreservation.
Subject(s)
Cryopreservation/methods , Leukocytes, Mononuclear/cytology , Neovascularization, Physiologic , AC133 Antigen , Antigens, CD/biosynthesis , Antigens, CD34/biosynthesis , Cell Adhesion , Cell Movement , Cell Survival , Flow Cytometry/methods , Glycoproteins/biosynthesis , Humans , Immunoglobulin G/metabolism , Lectins/chemistry , Lipoproteins, LDL/metabolism , Peptides , Phenotype , Time Factors , Vascular Endothelial Growth Factor Receptor-2/biosynthesisSubject(s)
Angiogenesis Inducing Agents/administration & dosage , Chemokine CXCL12/administration & dosage , Collagen Type I/chemistry , Drug Carriers , Ischemia/drug therapy , Muscle, Skeletal/blood supply , Stem Cells/drug effects , Alginates/chemistry , Angiogenesis Inducing Agents/chemistry , Animals , Cells, Cultured , Chemistry, Pharmaceutical , Chemokine CXCL12/chemistry , Chemotaxis/drug effects , Delayed-Action Preparations , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Compounding , Glucuronic Acid/chemistry , Hexuronic Acids/chemistry , Hindlimb , Humans , Injections, Intramuscular , Ischemia/pathology , Ischemia/physiopathology , Mice , Mice, Inbred C57BL , Microspheres , Neovascularization, Physiologic/drug effects , Particle Size , Rheology , Stem Cells/metabolism , Technology, Pharmaceutical/methodsABSTRACT
Biomaterials that have the ability to augment angiogenesis are highly sought-after for applications in regenerative medicine, particularly for revascularization of ischemic and infarcted tissue. We evaluated the culture of human circulating angiogenic cells (CAC) on collagen type I-based matrices, and compared this to traditional selective-adhesion cultures on fibronectin. Culture on a collagen matrix supported the proliferation of CD133(+) and CD34(+)CD133(+) CACs. When subjected to serum starvation, the matrix conferred a resistance to cell death for CD34(+) and CD133(+) progenitors and increased phosphorylation of Akt. After 4days of culture, phenotypically enriched populations of endothelial cells (CD31(+)CD144(+)) and progenitor cells (CD34(+)CD133(+)) emerged. Culture on matrix upregulated the phosphorylation and activation of ERK1/2 pathway members, and matrix-cultured cells also had an enhanced functional capacity for adhesion and invasion. These functional improvements were abrogated when cultured in the presence of ERK inhibitors. The formation of vessel-like structures in an angiogenesis assay was augmented with matrix-cultured cells, which were also more likely to physically associate with such structures compared to CACs taken from culture on fibronectin. In vivo, treatment with matrix-cultured cells increased the size and density of arterioles, and was superior at restoring perfusion in a mouse model of hindlimb ischemia, compared to fibronectin-cultured cell treatment. This work suggests that a collagen-based matrix, as a novel substrate for CAC culture, possesses the ability to enrich endothelial and angiogenic populations and lead to clinically relevant functional enhancements.